Spain / The Lancet

articulo 14.

Headlines and brief publisher-provided excerpts about articulo 14, with links to the original reports.

View all coverage of articulo 14 in Spain

Publisher coverage

From The Lancet.

1 REPORT

REPORT / 012026-02-05T08:00:00.000Z

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWGNhU3pjS0lJMVBlckZlSWh4djlqS2c5b285R3JsVVJ6T1ktSFBfaXRYWUU3UDBzWEt1VHNJZWlCWE04TnBFMUpyNVNIemxvNXFwQzZRazU2TWhFWHl5bmVIWi1HMVp6ZWtMLWJmVGNuZk14Q3RWUDBPenhuakpqUTNBZmxxRklYOHk0?oc=5" target="_blank">Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials</a>  <font color="#6f6f6f">The Lancet</font>

Read the original report

From The Lancet.

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials ↗

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials